The University of Strathclyde in Glasgow is home to around 25,000 students and 4,000 staff, placing useful learning and real-world impact at the heart of its activities.
Portfolio
10
companies
ClinSpec Diagnostics
ClinSpec Diagnostics develops rapid liquid biopsies for early cancer detection.
ClinSpec Dx
ClinSpec Dx develops blood test technology for the early detection of cancer.
Dxcover
Dxcover develops multiomic spectral analysis technology for early cancer detection.
Lupovis
Lupovis provides artificial intelligence driven deception environments for proactive cybersecurity defence.
Microplate Dx
Microplate Dx develops a rapid diagnostic platform to identify effective antibiotic treatments.
Northern Light Microscopy
Northern Light Microscopy builds compact super-resolution benchtop microscopes for bioscience laboratories.
R3-IoT
Satellite-enabled connectivity platform providing end-to-end data services for remote operations.
Regeno
Regeno develops modular, ground-serviced wind turbines to make wind power more accessible.
Sentinel
Digital platform advancing trauma support and mental health resources for frontline professionals.
Synaptec
Synaptec builds optical sensor technology for monitoring electric power grids.
Stuart Mackenzie
Commercialisation Infrastructure Manager
Stuart manages commercialisation infrastructure at the University of Strathclyde, having previously developed spin-out companies there. His background includes business development at Scottish Borders Enterprise and accountancy training at Touche Ross.
LinkedIn
Anne Henderson
Head of Investment
Anne brings investment and higher education experience, having previously worked at the Energy Investment Fund within Scottish Enterprise and the University of Strathclyde.
LinkedInThe oversubscribed round was led by DSW Ventures with backing from Scottish Enterprise, SWIM Capital and the University of Strathclyde.
"We’re excited to enter the next stage for Northern Light Microscopy. With the technology validated, this funding enables us to move forward into initial sales, scaling and product line expansion."
The funding round was supported by One Planet Capital, SFC Capital, Scottish Enterprise, and the British Business Bank.
"My main motivation was the huge opportunity to make an impact when I realized the potential of my idea. This started out as a dissertation on wind turbines and realized this could be so much more. I want to make a difference. We need clean energy fast to meet our targets we are behind on. Hence my inspiration to design a wind turbine that focused on lowering costs, improving logistics and eliminating the need for cranes and large teams to install and maintain wind turbines."
SFC Capital led the round with backing from the University of Strathclyde and Scottish Enterprise.
"The wellbeing of those who serve on the front lines is paramount. Sentinel exists to ensure that the people who protect and care for others receive the same care in return. This investment allows us to expand our impact and further develop our evidence-based tools for trauma prevention, management and recovery."
.png)
Eos Advisory led the Series A round alongside new and existing backers to fund international expansion and commercialisation.
"The Dxcover technology combines deep technical innovation with machine learning to radically change the diagnostic landscape. Over the last three years they have conclusively shown the accuracy and ease of use of their diagnostic test across multiple cancer indications. This is very much aligned with Eos’ approach to investing in innovation that has the potential to impact positively in people's lives. More recently the team at Dxcover have focused on building a world class international team on both sides of the Atlantic. This funding round is very much about commercialization in both the UK and the US."
The financing round includes contributions from Deepbridge Capital, Scottish Enterprise, SIS Ventures, Thairm Bio, and the University of Strathclyde to support clinical trials and commercial expansion.
"Our mission at Microplate Dx is to improve the quality of lives for patients by providing antimicrobial stewardship cost-effectively. Any delay in identifying the correct antibiotic for treatment can put lives at risks and huge pressure on clinical decision making, especially when the antibiotic sensitivity data that Microplate Dx can produce in an hour or less compared to the current approach that can take two days using existing techniques."
